Vacinação Página 3

NEJM - Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

The New England Journal of MedicineVaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle–encapsulated mRNA-based vaccine...

WHO - Evidence to recommendations for COVID-19 vaccines: Evidence framework

World Health OrganizationAs market-authorized COVID-19 vaccines become available, specific recommendations for the use of these vaccines will need to be issued. This SAGE evidence framework is intended to offer guidance for considering data...

ECDC - Overview of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA and the UK

European Centre for Disease Prevention and ControlThis report provides an initial overview of the national COVID-19 vaccination strategies and vaccine deployment plans in the countries of the European Union and European Economic Area (EU/EEA) and...

NEJ - Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

The New England Journal of MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective...

WHO - Draft landscape of COVID-19 candidate vaccines – 26 November 2020

World Health OrganizationThese landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in...

NEJM - Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

The New England Journal of MedicineWe recently reported the results of a phase 1 trial of a messenger RNA vaccine, mRNA-1273, to prevent infection with SARS-CoV-2; those interim results covered a period of 57 days after the first vaccination.

WHO - Guidance on developing a national deployment and vaccination Planning for COVID-19 vaccines

World Health Organization

The Guidance on National Deployment and Vaccination Planning is intended to help countries develop their plan for COVID-19 vaccine introduction.

ECDC - Key aspects regarding the introduction and prioritisation of COVID-19 vaccination in the EU/EEA and the UK

European Centre for Disease Prevention and ControlThis document provides an overview of the key aspects related to the initial phases following the introduction of one or more COVID-19 vaccines in the European Union and European Economic Area...

JAMA - Reassuring the Public and Clinical Community About the Scientific Review and Approval of a COVID-19 Vaccine

JAMA NETWORKPublic perception of the review of medications and vaccines for coronavirus disease 2019 (COVID-19) has become enmeshed in politics. The pressure on the US Food and Drug Administration (FDA) and Commissioner Stephen Hahn, MD, to...

The Lancet - Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

The LancetWe developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndrome...

NEJM - Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

The New England Journal of MedicineNVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant.

JAMA - Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials

JAMA NETWORK

What are the safety and immunogenicity of an inactivated vaccine against coronavirus disease 2019 (COVID-19)?

NEJM - Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

The New England Journal of MedicineVaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower...

The Lancet - Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

The LancetThe pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike...

LANCET - Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

The LancetThis is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate...